摘要
药物涂层支架通过在金属支架表面涂层抗狭窄药物,抑制血管平滑肌细胞的过度增生,有效地预防了支架内再狭窄的形成。目前研究和应用得最为广泛的是雷帕霉素和紫杉醇药物涂层支架。本文将对雷帕霉素和紫杉醇药物涂层支架的临床研究结果进行比较,并对影响两种药物涂层支架临床疗效的因素进行论述。
出处
《国际心血管病杂志》
2006年第3期147-150,共4页
International Journal of Cardiovascular Disease
参考文献17
-
1[1]Stone GW,Ellis SG,Cox DA,et al.A polymer-based,paclitaxel-eluting stent in patients with coronary artery disease[J].N Engl J Med,2004,350(3):221-231.
-
2[2]Tanabe K,Serruys PW,Grube E,et al.TAXUS Ⅲ Trial:in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation[J].Circulation,2003,107(4):559-564.
-
3[3]Grube E,Silber S,Hauptmann KE,et al.TAXUS Ⅰ:sixand twelve-month results from a randomized,double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions[J].Circulation,2003,107(1):38-42.
-
4[4]Mauri L,Orav EJ,Candia SC,et al.Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials[J].Circulation,2005,112(18):2833-2839.
-
5[5]Morice MC,Serruys PW,Colombo A,et al.Eight-month outcome of the REALITY study:a prospective,randomized,multi-center head-to -head comparison of the sirolimuseluting stent (Cypher) and the paclitaxel-eluting stent (Taxus)[C].// American College of Cardiology.2005 Annual Scientific Session of the American College of Cardiology,Orlando,Fla.,March 6-9,C2005
-
6[6]Windecker S,Remondino A,Eberli FR,et al.Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization[J].N Engl J Med,2005,353(7):653-662.
-
7[7]Sherr CJ,Roberts JM.CDK inhibitors:positive and negative regulators of G1-phase progression[J].Genes Dev,1999,13(12):1501-1512.
-
8[8]Abal M,Andreu JM,Barasoain I.Taxanes:microtubule and centrosome targets,and cell cycle dependent mechanisms of action[J].Curr Cancer Drug Targets,2003,3 (3):193-203.
-
9[9]Grube E,Lansky A,HauPtmann KE,et al.High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization:one-year results from the SCORErandomized trial[J].J Am Coll Cardiol,2004,44(7):1368-1372.
-
10[10]Gervasoni JE Jr,Hindenburg AA,Vezeridis MP,et al.An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and daunorubicin by induction of both necrosis and apoptosis[J].Anticancer Res,2004,24(5A):2617-2626.
同被引文献15
-
1顾兴中,易红,倪中华.冠状动脉支架研究[J].中国生物医学工程学报,2005,24(6):662-667. 被引量：7
-
2高润霖.药物洗脱支架研究现状及进展[J].中国实用内科杂志,2006,26(8):1121-1123. 被引量：19
-
3Kang SH,Park KH,Choi DJ. Coronary artery bypass grafting versus drug-eluting stent implantation for left main coronary artery disease (from a Two-Center Registry)[J].The American Journal of Cardiology,2010.343-351.
-
4Nordmann AJ,Briel M,Bucher HC1. Mortality in randomized con-trolled trials comparing drug-eluting vs.bare metal stents in coro-nary artery disease:a meta-analysis[J].{H}EUROPEAN HEART JOURNAL,2006.2784-2814.
-
5Serruys PW,Sianos G,Abizaid A. The paclitaxel in-stent controlled elution study (PISCES):the effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform[J].Journal of the American College of Cardiol-ogy,2005,(02):253-260.
-
6Vahab Dehlaghi,Mohammad Tafazoli Shadpoor,Siamak Najarian. A-nalysis of wall shear stress in stented coronary artery using 3D compu-tational fluid dynamics modeling[J].J Materials Processing Technol-ogy,2008.174-181.
-
7Balakrishnan B,Tzafriri AR,Seifert P. Strut position,blood flow and drug deposition:implications for single and overlapping drugeluting stents[J].{H}CIRCULATION,2005,(22):2958-2965.
-
8Ghanashyam Acharya,Kinam Park. Mechanisms of controlled drug release from drug-eluting stents[J].Advanced Drug Delivery Re-views,2006.387-401.
-
9Schwartz SM. Smooth muscle migration in atherosclerosis and rest-enosis[J].{H}Journal of Clinical Investigation,1997,(11 Suppl):87-89.
-
10Sheer CJ,Roberts JM. CDK inhibitors:positive and negative regula-tors of G1-phase progression[J].{H}Genes and development,1999,(12):1501-1512.
-
1李珍.替罗非班联合药物涂层支架治疗急性心肌梗死的护理[J].护理与康复,2008,7(1):47-48. 被引量：3
-
2陈莲芳,梁洪球,袁小玲,周金凤.紫杉醇涂层支架植入术治疗冠心病的护理[J].现代护理,2005,11(13):1012-1013. 被引量：5
-
3陈波,杨志健.药物涂层支架预防冠状动脉再狭窄的研究进展[J].南京医科大学学报（自然科学版）,2003,23(5):504-506.
-
4陈金锋,党群,金喆,李永健.药物涂层支架在冠心病合并糖尿病患者中的应用现状[J].医学综述,2012,18(13):2078-2080. 被引量：1
-
5李媛,邹隽,吴少杰.经皮冠状动脉介入手术围手术期的护理配合[J].中国处方药,2015,13(3):136-137. 被引量：1
-
6罗榕翠.经皮冠状动脉药物涂层支架植入的护理体会[J].海南医学,2011,22(4):148-149.
-
7何青.从循证医学看使用药物涂层支架的临床意义[J].中国心血管杂志,2009,14(2):81-83. 被引量：2
-
8韩雅君,任志亮,鄂路莎.药物涂层支架面临的挑战[J].内蒙古医学杂志,2006,38(10):882-885.
-
9对STEMI患者应避免置入药物涂层支架[J].中华医学信息导报,2009,24(6):7-7.
-
10林松,陈绍良,叶飞,马玉玲,朱中生,张俊杰,段宝祥.不同负荷剂量氯吡格雷对植入药物洗脱支架患者术后影响[J].江苏医药,2007,33(10):984-986. 被引量：1
